ADMA Biologics was trading poorly in early 2021, near $2 per share. My thesis centered on ADMA's asset value, including plasma centers, matching its enterprise value. Strong revenue growth, insider ...
ADMA Biologics remains a Buy as Q3 results and 2026 guidance support a bullish long-term outlook. ADMA's Asceniv drives robust revenue and margin expansion, with 2026 revenue guided at $630M and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results